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Peter Lattke1, Stephan Glöckner2,4, Anthony Stell4, Aleksander Prejbisz5,
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Abstract
Background: Medication-related interferences with measurements of catecholamines and their metabolites represent
important causes of false-positive results during diagnosis of phaeochromocytomas and paragangliomas (PPGLs). Such
interferences are less troublesome with measurements by liquid chromatography with tandem mass-spectrometry
(LC-MS/MS) than by other methods, but can still present problems for some drugs. Levodopa, the precursor for
dopamine used in the treatment of Parkinson’s disease, represents one potentially interfering medication.
Methods: Plasma and urine samples, obtained from 20 Parkinsonian patients receiving levodopa, were analysed for
concentrations of catecholamines and their O-methylated metabolites by LC-MS/MS. Results were compared with those
from a group of 120 age-matched subjects and 18 patients with PPGLs.
Results: Plasma and urinary free and deconjugated (freeþ conjugated) methoxytyramine, as well as urinary dopamine,
showed 22- to 148-fold higher (P< 0.0001) concentrations in patients receiving levodopa than in the reference group. In
contrast, plasma normetanephrine, urinary noradrenaline and urinary free and deconjugated normetanephrine concen-
trations were unaffected. Plasma free metanephrine, urinary adrenaline and urinary free and deconjugated metanephrine
all showed higher (P< 0.05) concentrations in Parkinsonian patients than the reference group, but this was only a
problem for adrenaline. Similar to normetanephrine, plasma and urinary metanephrine remained below the 97.5 per-
centiles of the reference group in almost all Parkinsonian patients.
Conclusions: These data establish that although levodopa treatment confounds identification of PPGLs that produce
dopamine, the therapy is not a problem for use of LC-MS/MS measurements of plasma and urinary normetanephrine and
metanephrine to diagnose more commonly encountered PPGLs that produce noradrenaline or adrenaline.
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Introduction
Medication-associated interferences with measurements
of plasma and urinary catecholamines and metabolites
as a cause of false-positive test results during diagnosis
of phaeochromocytomas and paragangliomas (PPGLs)
are wide-ranging, but in general present in two main
forms: (1) pharmaco-physiological effects and (2) direct
interference with the analytical method. One of the
most common pharmaco-physiological causes of false-
positive test results during diagnosis of PPGLs involves
the effect of tricyclic antidepressants and related drugs
to block sympathoneuronal reuptake of noradrenaline
and thereby increase plasma and urinary concentra-
tions of the amine and its metabolites.1–4 Direct analyt-
ical interferences with high-performance liquid
chromatography electrochemical detection (HPLC-
ECD)-based measurements of plasma or urinary cat-
echolamines and their O-methylated metabolites can
result from numerous medications, including labeto-
lol,5,6 buspirone,7 acetaminophen,8,9 mesalamine10 and
its prodrug, sulphasalazine.11
While pharmaco-physiological causes of false-posi-
tive results during diagnosis of PPGLs are method
independent, those involving analytical interferences
are usually method and analyte specific. Analytical
interference is less of a problem for liquid chromatog-
raphy with tandem mass spectrometry (LC-MS/MS)-
based methods than less analytically specific methods,
such as HPLC-ECD.12 Nevertheless, certain medica-
tions remain a problem for LC-MS/MS. Levodopa in
particular, as a prodrug for dopamine used for treat-
ment of Parkinson’s disease and sometimes for restless
legs syndrome, can be metabolized by pathways that
lead to numerous products with significant potential
for both analytical interference and pharmaco-physio-
logical increases in concentrations of catecholamines
and their metabolites.13–19
Davidson et al.17 recently showed that levodopa not
only resulted in substantially raised urinary outputs of
dopamine and homovanillic acid, but also of free nor-
metanephrine and metanephrine, the respective
O-methylated metabolites of noradrenaline and adren-
aline. These findings indicated reduced diagnostic value
of the analytes as indicators of PPGLs in patients
taking levodopa, a conclusion particularly troubling
for measurements of plasma or urinary normetanephr-
ine and metanephrine as the now recommended first-
line tests for diagnosis of the tumours.20
The study by Davison et al.,17 nevertheless, involved
HPLC-ECD measurements of urinary free normeta-
nephrine and metanephrine. It thus remains unclear
whether measurements by LC-MS/MS pose similar
problems or if measurements of plasma free normeta-
nephrine and metanephrine are also affected by levo-
dopa therapy. It is also unknown to what extent
levodopa therapy affects measurements of plasma and
urinary methoxytyramine, the O-methylated metabolite
of dopamine now proposed as an additional useful bio-
marker for identification of PPGLs characterized by
excessive dopamine production.21–23
Although PPGLs in patients with Parkinson’s dis-
ease have only rarely been described,24 numerous
reports in Parkinsonian patients of false-positive test
results, pseudophaeochromocytoma or hypertensive
crises,13–16,18,19,25–27 indicate that suspicion of catecho-
lamine-producing tumours in such patients is not infre-
quent. This underscores the importance of a reliable
diagnostic test for this particular clinical presentation.
The aim of the present study was therefore to examine
the influences of levodopa therapy on LC-MS/MS
measurements of plasma free and urinary free and
deconjugated (conjugatedþ free) normetanephrine,
metanephrine and methoxytyramine. Since advanced
age has substantial impact on plasma concentrations
of normetanephrine,28,29 the study included an age-
matched reference group for comparison and a third
group of age-matched patients with PPGLs.
Subjects and methods
Subjects
Subjects included 20 patients treated with levodopa for
Parkinson’s disease, a reference group of 120 age-
matched volunteers or patients tested for PPGLs and
a third group of 18 age-matched patients with patho-
logically confirmed PPGLs (Table 1).
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Patients with Parkinson’s disease received levodopa
in doses of 100–200mg three times daily. Levodopa was
delivered to all patients in combination with a DOPA
decarboxylase inhibitor (carbidopa or benserazide).
Twelve of these patients also received dopamine agonist
therapy with ropinirole (n¼ 5), pramipexole (n¼ 5) or
piribedil (n¼ 2). Additionally, two patients received the
selective monoamine oxidase B (MAO-B) inhibitor,
rasagaline, and one other patient the catechol-
O-methyltransferase (COMT) inhibitor, entacapone.
Eight patients also received antihypertensive treatment
with one or more of the following drugs: hydrochlor-
othiazide, furosemide, xipamide, amlodipine, losartan,
candesartan, ramipril, lisinopril, enalapril, bisoprolol,
metoprolol and aliskiren. Other medications included
amantadine, domperidone, mirtazapine, venlafaxine,
clozapine, duloxetine, rivaroxaban, simvastatin, brimo-
nidine, memantine, gabapentin, tramadol, zopiclone,
allopurinol, oxibutynin, pantoprazole and L-thyroxine.
The 120 subjects in the age-matched reference group
were selected from larger populations of 165 normoten-
sive and hypertensive volunteers and 533 patients tested
for PPGLs and in whom tumours were not detected.
Selection of subjects into the reference group was based
primarily on advanced age with secondary consider-
ation of gender. Similarly, the 18 age-matched patients
with PPGLs were selected on the basis of advanced age
from a larger group of 74 patients with tumours.
PPGLs were confirmed in all patients either on the
basis of histopathological examination of resected
tumours or in two cases with inoperable metastatic dis-
ease, by prior history and findings of metastatic disease
by imaging studies.
Patients with Parkinson’s disease were all enrolled
and evaluated under a clinical protocol at the
University Hospital of Dresden, whereas subjects in
the other groups were enrolled under a multicentre
protocol (the prospective monoamine-producing
tumour study https://pmt-study.pressor.org) involving
four institutions: (1) University Hospital of Dresden,
Dresden, Germany; (2) Institute of Cardiology,
Warsaw, Poland; (3) University Hospital Würzburg,
Würzburg, Germany and (4) Medizinische Klinik und
Poliklinik IV, Klinikum der Universität München,
Munich, Germany. All subjects provided written
informed consent under protocols approved by the
local Ethics Committees at each Centre.
Collections of blood and urine samples
Samples of heparinized blood (8mL) were collected
according to instructions requiring the draw after at
least 20min of supine rest. Samples were placed on
ice or stored refrigerated until centrifuged (4C) to sep-
arate plasma, which was stored at 80C until assayed.
For the patients with Parkinson’s disease, blood was
drawn on an average 3 h (range 0.5–8 h) after the last
dose of levodopa. Random urine samples (5mL) were
collected within an hour before or after blood collec-
tions and stored at 4C until aliquoting and storage
at 80C within the day of collection. All other urine
samples were collected as 24-hour specimens as
described previously.30 Samples of plasma and urine
from the three participating centres outside of
Dresden were all delivered frozen on dry ice to the
Dresden analytical laboratory.
Laboratory analyses
Measurements of plasma concentrations of free norme-
tanephrine, metanephrine and methoxytyramine were
by LC-MS/MS as detailed elsewhere.23 Intra-assay
coefficients of variation ranged from 2.9% for high
concentrations to 13.5% for low concentrations, while
inter-assay coefficients of variation ranged from 6.7%
to 11.4%.
Measurements of urinary free normetanephrine,
metanephrine and methoxytyramine utilized a similar
LC-MS/MS method with modifications that allowed
simultaneous measurements of urinary noradrenaline,
adrenaline and dopamine.30 The same assay in a differ-
ent chromatographic run also enabled measurements of
urinary deconjugated normetanephrine, metanephrine
and methoxytyramine following an acid hydrolysis
procedure as detailed previously.30 Intra-assay coeffi-
cients of variation ranged from 2.7% to 10.3%, while
inter-assay coefficients of variation ranged from 6.3%
to 13.6%. Measurements of urinary analytes were
expressed as ratios of analytes to creatinine (mmol/
mol creatinine).
Additional measurements of plasma concentrations
of levodopa, dopamine and 3,4-dihydroxyphenylacetic
acid (DOPAC), the deaminated metabolite of dopa-
mine, were carried out in all specimens from patients
with Parkinson’s disease and in a subset of specimens
from 20 subjects in the reference group. These
measurements were by HPLC-ECD with an alumina
extraction procedure for specimen purification and
Table 1. Characteristics of patient populations.
Reference
population
Parkinson’s
disease
patients
Phaeochromocytoma
and paraganglioma
patients
N 120 20 18
Age (mean
and range)
70 (59–83) 72 (59–83) 68 (61–82)
Gender (F/M) 65/55 8/12 9/9
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enrichment prior to injection onto the HPLC column.31
Intra-assay and inter-assay coefficients of variation for
this assay ranged from 2.5% to 11.0%.
Statistics
Statistical analyses utilized the JMP statistics software
package (SAS Institute Inc, Cary, NC). Because plasma
and urinary concentrations of the measured analytes
show non-normal distributions, results for these ana-
lytes are presented as medians and ranges with upper
cut-offs for the reference population established using
the 97.5 percentiles of distributions.32 Wilcoxon tests
were used for two-group comparisons, whereas the
Steel–Dwass method was used for non-parametric
comparisons among all pairs for three groups.
Significance of relationships was determined using
Spearman’s test.
Results
Plasma levodopa, dopamine and DOPAC
Median plasma concentrations of levodopa in
Parkinson’s patients were 564-fold higher (P< 0.0001)
than concentrations in the 20 subjects from the refer-
ence population in whom these plasma measurements
were carried out (Table 2). Plasma concentrations of
dopamine and DOPAC were also substantially higher
(P< 0.0001) in patients with Parkinson’s disease than
reference subjects, but with respective 32- and 11-fold
differences that were substantially lower (P< 0.0001)
than the 564-fold difference for levodopa.
Among patients with Parkinson’s disease, plasma
concentrations of levodopa, dopamine and DOPAC
varied widely, but showed no relationship to doses of
levodopa with and without consideration of time
from the last dose before blood samples were drawn.
While plasma concentrations of levodopa were posi-
tively correlated with those of DOPAC (rs¼ 0.73,
P¼ 0.0003), there were no relationships of plasma
dopamine to either levodopa or DOPAC (data not
shown).
Plasma free normetanephrine, metanephrine
and methoxytyramine
Plasma concentrations of free normetanephrine in
patients with Parkinson’s disease treated with levodopa
did not differ from concentrations in the age-matched
reference group, but were 6-fold higher (P< 0.0001) in
patients with PPGLs than in the Parkinsonian group
(Figure 1(a)). In contrast to plasma normetanephrine,
plasma concentrations of free metanephrine were 40%
higher (P¼ 0.002) in patients with Parkinson’s disease
than in the reference group (Figure 1(b)). Similar to
normetanephrine, plasma concentrations of free meta-
nephrine were 7-fold higher (P< 0.005) in patients with
PPGLs than in patients with Parkinson’s disease.
Plasma concentrations of free methoxytyramine, how-
ever, were respectively 61- and 39-fold higher in
Parkinsonian patients receiving levodopa than in the
reference group and patients with PPGLs (Figure 1(c)).
None of the Parkinsonian patients treated with levo-
dopa had plasma concentrations of normetanephrine
above the upper cut-offs of the reference group
(Figure 1(a)). Furthermore, only one patient had
plasma concentrations of metanephrine above the
upper cut-offs (Figure 1(b)). In contrast, plasma con-
centrations of methoxytyramine for all patients treated
with levodopa were increased by more than 10-fold
above the upper cut-offs of the reference group
(Figure 1(c)).
Urinary catecholamines and O-methylated
metabolites
Similar to the findings for plasma normetanephrine
(Figure 1(a)), urinary concentrations of noradrenaline
and free and deconjugated normetanephrine, expressed
as ratios to urinary creatinine concentrations, showed
no differences between patients with Parkinson’s
disease treated with levodopa and the reference popu-
lation (Figure 2(a), (d) and (g)). None of the levodopa-
treated Parkinsonian patients showed urinary outputs
of noradrenaline or normetanephrine above the 97.5
percentiles of the reference group and only one patient
Table 2. Plasma concentrations (medians and ranges) of levodopa, dopamine and DOPAC in Parkinson’s disease
patients compared to reference subjects.
Reference subjects Parkinson’s disease patients
N 20 20
Plasma levodopa (nmol/L) 7.8 (1.6–14.4) 4403 (299–11,527)*
Plasma dopamine (nmol/L) 0.22 (0.02–0.67) 7.0 (0.3–99.9)*
Plasma DOPAC (nmol/L) 8.7 (4.5–17.6) 92 (17–322)*
*P< 0.0001 compared to reference.
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showed outputs of urinary deconjugated normeta-
nephrine above the cut-offs.
In contrast to noradrenaline and its O-methylated
metabolites, but similar to the findings for plasma
metanephrine (Figure 1(b)), creatinine-normalized
urinary outputs of adrenaline and free and deconju-
gated metanephrine were consistently higher
(P< 0.05) in patients treated with levodopa than in
the reference population (Figure 2(b), (e) and (h)).
The difference was particularly prominent for urinary
adrenaline, which showed 3.6-fold higher (P< 0.0001)
outputs in Parkinson’s patients than in the reference
group; moreover, urinary outputs of adrenaline were
above the upper cut-offs for the reference group in at
least half of all Parkinsonian patients. In comparison,
urinary outputs of free and deconjugated metanephrine
were, respectively, only 37% and 48% higher (P< 0.05)
in patients with Parkinson’s disease than in the refer-
ence group; almost all concentrations in the patient
group were within the upper cut-offs of the reference
group.
Also similar to findings for plasma methoxytyramine
(Figure 1(c)), urinary dopamine and free and deconju-
gated methoxytyramine were all substantially higher
(P< 0.0001) in levodopa-treated patients than in both
reference and PPGL patient groups (Figure 2(c), (f) and
(i)). Increases were particularly prominent for urinary
dopamine, which showed 148-fold higher concentra-
tions in levodopa-treated patients than in the refer-
ence group, compared to 56- and 22-fold higher
respective urinary outputs for free and deconjugated
methoxytyramine.
Patients with PPGLs
All except four patients with PPGLs had plasma con-
centrations of normetanephrine above the 97.5 percent-
iles of the reference group, but three of these four had
elevated plasma concentrations of metanephrine while
one had solitary elevations of plasma methoxytyramine
(Figure 1(a), (b) and (c)). Similarly, all except a few
patients with PPGLs showed increases in urinary free
and deconjugated normetanephrine above the upper
cut-offs of the reference group (Figure 2(d) and (e)),
but among those, all had increases of either urinary
metanephrine or methoxytyramine (Figure 2(e), (f),
(h) and (i)).
In contrast to normetanephrine, urinary noradren-
aline in patients with PPGLs showed concentrations
under the upper cut-offs of the reference group in
nearly one-half of all patients (Figure 2(a)). Thus, urin-
ary noradrenaline in patients with PPGLs was only
increased (P< 0.0001) by 2.4-fold above concentrations
in the reference group compared to respective 6.4- and
3.8-fold differences (P< 0.0001) for urinary free and
deconjugated normetanephrine (Figure 2(d) and (g))
and a 8.3-fold difference (P< 0.0001) for plasma free
normetanephrine (Figure 1(a)). In comparison, plasma
metanephrine, urinary adrenaline and urinary free
and deconjugated metanephrine showed similar 10- to
Figure 1. Dot and box-plots of plasma concentrations of free normetanephrine (a), metanephrine (b) and methoxytyramine (c) in
the reference group (REF), in patients with Parkinson’s disease receiving levodopa (PARK) and in patients with PPGLs (PPGL). The
dashed horizontal lines with values immediately above represent the 97.5 percentiles for distributions in the reference population.
P values for differences between groups are illustrated at the top of each panel (NS, not significant). The different symbols (# ˙ ) for
patients with PPGLs serve to illustrate patients with elevations of methoxytyramine, but not always elevations of normetanephrine or
metanephrine (#), patients with elevations of metanephrine, but not always normetanephrine or methoxytyramine () and patients
with elevations of normetanephrine, but not always elevations of metanephrine or methoxytyramine (˙).
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Figure 2. Dot and box-plots of creatinine-normalised urinary outputs of noradrenaline (a), adrenaline (b), dopamine (c), free
normetanephrine (d), free metanephrine (e), free methoxytyramine (f), deconjugated normetanephrine (g), deconjugated meta-
nephrine (h) and deconjugated methoxytyramine (i) in the reference group (REF), in patients with Parkinson’s disease receiving
levodopa (PARK) and in patients with PPGLs (PPGL). The dashed horizontal lines with values immediately above represent the 97.5
percentiles for distributions in the reference population. P values for differences between groups are illustrated at the top of each
panel (NS, not significant).
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12-fold higher concentrations in patients with PPGLs
than in the reference group (Figure 1(b) and Figure
2(b), (e) and (h)). Plasma concentrations of methoxy-
tyramine were 58% higher (P¼ 0.0135) among patients
with PPGLs than in the reference group (Figure 1(c)),
with slightly lower but still significant (P< 0.04) 27%
and 33% respective differences also observed for
urinary free and deconjugated methoxytyramine
(Figure 2(f) and (i)). In contrast, urinary dopamine
did not differ between patients with PPGLs and the
reference group (Figure 2(c)).
Discussion
This study establishes that while levodopa therapy con-
founds identification of PPGLs that produce dopamine,
the drug is not a problem for the diagnosis of more
commonly encountered noradrenaline or adrenaline-
producing PPGLs. Our findings that plasma concentra-
tions and urinary outputs of normetanephrine and
metanephrine are largely unaffected by levodopa ther-
apy contrasts with findings by Davidson et al.,17 who
described urinary concentrations of free normetanephr-
ine and metanephrine on average 2.2- to 4.8-fold higher
in Parkinsonian patients receiving levodopa than in
levodopa free patients and control subjects. These
investigators concluded that levodopa therapy
decreases the utility of measurements of urinary free
normetanephrine and metanephrine for diagnosis
of PPGLs.
The above conclusion, however, was based on meas-
urements by HPLC-ECD, whereas the present findings
of minimal influence of levodopa on plasma free nor-
metanephrine and metanephrine as well as the urinary
free and deconjugated metabolites was based on meas-
urements by LC-MS/MS. Mass spectrometric methods,
in which detection involves multiple reaction monitor-
ing of precursor and product ions, offer improved
specificity and relative freedom from analytical
interferences compared to other methods, such as
HPLC-ECD.
Apart from metabolism to dopamine, and poten-
tially to downstream catecholamines and their metab-
olites, levodopa may also be metabolized by other
pathways to numerous products, such as dihydroxy-
phenylpyruvic acid, 3-O-methyldopa and vanillactic
acid.33,34 Such products have potential for analytical
interference, a separate source of false-positive results
from the well-established pharmaco-physiological
effects of levodopa to substantially increase plasma
and urinary excretion of dopamine and dopamine
metabolites, such as DOPAC, homovanillic acid and
methoxytyramine.33,35 The present findings of substan-
tially increased plasma and urinary excretion of meth-
oxytyramine after levodopa is in agreement with the
latter observations, establishing that measurements of
this metabolite in both plasma and urine cannot be
used to identify dopamine-producing PPGLs in
patients taking levodopa.
Interestingly, while urinary noradrenaline and
plasma and urinary normetanephrine were unaffected
by levodopa therapy, adrenaline in urine and its
O-methylated metabolites in both plasma and urine
were consistently higher in Parkinsonian patients trea-
ted with levodopa than in age-matched controls.
Nevertheless, while the difference for urinary adren-
aline was clear, the differences for metanephrine mea-
sured in both plasma and urine were relatively minor.
More importantly, as shown by the comparisons with
the reference group and patients with PPGLs, the small
magnitude of the increases in plasma and urinary meta-
nephrine in the patients with Parkinson’s disease is
unlikely to significantly impact the utility of these meas-
urements for diagnosis of PPGLs.
The reason for the 3.6-fold higher urinary outputs of
adrenaline and smaller increases of metanephrine in the
Parkinsonian compared to the reference group is
unclear and not entirely consistent with earlier stu-
dies,17,36–38 some of which have indicated either no dif-
ferences or even lowered concentrations of urinary
adrenaline in Parkinsonian patients.37,38 Nevertheless,
there have been two reports of increased urinary adren-
aline excretion in Parkinsonian patients, but in both
cases this was only observed while patients were not
receiving levodopa.17,36 Possibly, therefore, the pres-
ently observed increases in urinary excretion of adren-
aline and metanephrine in the Parkinsonian group are
unrelated to any direct influence of levodopa.
While the minimal influence of levodopa on plasma
and urinary normetanephrine and metanephrine is not
in agreement with the study of Davidson et al.,17 these
findings are in agreement with other studies showing
little influence of levodopa on noradrenaline and its
metabolites,33,37 including in some studies minimal
effect on urinary excretion of deconjugated normeta-
nephrine and metanephrine.35,38 From the comparisons
of the results of Parkinsonian patients with the age-
matched patients with PPGLs and the reference popu-
lation, it is clear that measurements of plasma and urin-
ary normetanephrine and metanephrine by LC-MS/MS
can be used to reliably diagnose PPGLs in patients
taking levodopa.
A limitation of this study was that Parkinsonian
patients, besides receiving levodopa combined with
a dopa-decarboxylase inhibitor, were all receiving
highly variable combinations of other medications.
These medications included MAO-B or COMT inhibi-
tors and antidepressants, all with significant potential
for influences on the metabolism or disposition of cat-
echolamines. Dopamine agonist therapy can also
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influence sympathoadrenal activity in divergent direc-
tions, with increases in adrenaline release.39 While the
highly variable combinations of medications confounds
interpretation of some of the findings, such as the
increased urinary excretion of adrenaline and lesser
increases in metanephrine, this is not a problem for
the primary conclusions of the study concerning the
minimal impact of levodopa therapy on plasma and
urinary normetanephrine and metanephrine. In fact,
the highly variable combinations of medications reflects
the clinical scenario that can be expected with testing in
Parkinsonian patients, providing additional confidence
that other medications commonly used in these patients
are not overtly troublesome for diagnosis of PPGLs.
In summary, with LC-MS/MS-based measurements
of plasma free or urinary free or deconjugated norme-
tanephrine and metanephrine, excluding or confirming
PPGLs in patients on levodopa therapy should no
longer be considered a significant diagnostic challenge.
Acknowledgements
Thanks are extended to Carmen Berndt and Nan Qin for
technical assistance and Drs Roland Därr, Dirk Weismann
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